Published in Gastroenterology on January 05, 2012
Identification of Sox9-dependent acinar-to-ductal reprogramming as the principal mechanism for initiation of pancreatic ductal adenocarcinoma. Cancer Cell (2012) 3.36
MicroRNA array analysis finds elevated serum miR-1290 accurately distinguishes patients with low-stage pancreatic cancer from healthy and disease controls. Clin Cancer Res (2013) 2.71
EGF receptor signaling is essential for k-ras oncogene-driven pancreatic ductal adenocarcinoma. Cancer Cell (2012) 2.59
Mutant GNAS detected in duodenal collections of secretin-stimulated pancreatic juice indicates the presence or emergence of pancreatic cysts. Gut (2012) 2.17
Mutant TP53 in duodenal samples of pancreatic juice from patients with pancreatic cancer or high-grade dysplasia. Clin Gastroenterol Hepatol (2012) 1.99
KRAS: feeding pancreatic cancer proliferation. Trends Biochem Sci (2014) 1.85
KRAS and guanine nucleotide-binding protein mutations in pancreatic juice collected from the duodenum of patients at high risk for neoplasia undergoing endoscopic ultrasound. Clin Gastroenterol Hepatol (2014) 1.81
Oncogenic KRAS signalling in pancreatic cancer. Br J Cancer (2014) 1.71
Roles for KRAS in pancreatic tumor development and progression. Gastroenterology (2013) 1.61
KLF4 Is Essential for Induction of Cellular Identity Change and Acinar-to-Ductal Reprogramming during Early Pancreatic Carcinogenesis. Cancer Cell (2016) 1.49
Genetic basis of pancreas cancer development and progression: insights from whole-exome and whole-genome sequencing. Clin Cancer Res (2012) 1.47
Hif1a Deletion Reveals Pro-Neoplastic Function of B Cells in Pancreatic Neoplasia. Cancer Discov (2015) 1.34
The early detection of pancreatic cancer: what will it take to diagnose and treat curable pancreatic neoplasia? Cancer Res (2014) 1.32
Metastatic pancreatic cancer is dependent on oncogenic Kras in mice. PLoS One (2012) 1.27
Evolution and dynamics of pancreatic cancer progression. Oncogene (2013) 1.25
Interleukin-6 is required for pancreatic cancer progression by promoting MAPK signaling activation and oxidative stress resistance. Cancer Res (2013) 1.24
Kras as a key oncogene and therapeutic target in pancreatic cancer. Front Physiol (2014) 1.19
Loss of the transcription factor GLI1 identifies a signaling network in the tumor microenvironment mediating KRAS oncogene-induced transformation. J Biol Chem (2013) 1.18
Genetics and biology of pancreatic ductal adenocarcinoma. Genes Dev (2016) 1.13
CDK4/6 inhibitors have potent activity in combination with pathway selective therapeutic agents in models of pancreatic cancer. Oncotarget (2014) 1.10
A Revised Classification System and Recommendations From the Baltimore Consensus Meeting for Neoplastic Precursor Lesions in the Pancreas. Am J Surg Pathol (2015) 1.09
High-fat, high-calorie diet promotes early pancreatic neoplasia in the conditional KrasG12D mouse model. Cancer Prev Res (Phila) (2013) 1.08
CD4+ T lymphocyte ablation prevents pancreatic carcinogenesis in mice. Cancer Immunol Res (2014) 1.06
Recent advances in the molecular diagnostics of gastric cancer. World J Gastroenterol (2015) 1.01
Pancreatic cancer biology and genetics from an evolutionary perspective. Nat Rev Cancer (2016) 0.98
High mesothelin expression in advanced lung adenocarcinoma is associated with KRAS mutations and a poor prognosis. Oncotarget (2015) 0.97
Exome capture sequencing of adenoma reveals genetic alterations in multiple cellular pathways at the early stage of colorectal tumorigenesis. PLoS One (2013) 0.97
Perspectives in the treatment of pancreatic adenocarcinoma. World J Gastroenterol (2015) 0.97
IER3 supports KRASG12D-dependent pancreatic cancer development by sustaining ERK1/2 phosphorylation. J Clin Invest (2014) 0.96
Clinical utility of circulating tumor DNA for molecular assessment in pancreatic cancer. Sci Rep (2015) 0.96
GeLC-MRM quantitation of mutant KRAS oncoprotein in complex biological samples. J Proteome Res (2012) 0.95
Molecular pathways in pancreatic carcinogenesis. J Surg Oncol (2012) 0.95
HLA ligandome tumor antigen discovery for personalized vaccine approach. Expert Rev Vaccines (2013) 0.94
GNAS and KRAS mutations are common in intraductal papillary neoplasms of the bile duct. PLoS One (2013) 0.93
GNAS sequencing identifies IPMN-specific mutations in a subgroup of diminutive pancreatic cysts referred to as "incipient IPMNs". Am J Surg Pathol (2014) 0.92
Prolonged survival and delayed progression of pancreatic intraepithelial neoplasia in LSL-KrasG12D/+;Pdx-1-Cre mice by vitamin E δ-tocotrienol. Carcinogenesis (2013) 0.91
MAPK signaling is required for dedifferentiation of acinar cells and development of pancreatic intraepithelial neoplasia in mice. Gastroenterology (2013) 0.91
Inherited pancreatic cancer syndromes. Cancer J (2012) 0.90
Pathology of pancreatic ductal adenocarcinoma: facts, challenges and future developments. World J Gastroenterol (2014) 0.90
Molecular Biologic Approach to the Diagnosis of Pancreatic Carcinoma Using Specimens Obtained by EUS-Guided Fine Needle Aspiration. Gastroenterol Res Pract (2012) 0.89
Genome-wide somatic copy number alterations in low-grade PanINs and IPMNs from individuals with a family history of pancreatic cancer. Clin Cancer Res (2012) 0.89
Deep sequencing of cancer-related genes revealed GNAS mutations to be associated with intraductal papillary mucinous neoplasms and its main pancreatic duct dilation. PLoS One (2014) 0.88
Diversity of clinical implication of B-cell translocation gene 1 expression by histopathologic and anatomic subtypes of gastric cancer. Dig Dis Sci (2014) 0.88
KRAS(G12D)- and BRAF(V600E)-induced transformation of murine pancreatic epithelial cells requires MEK/ERK-stimulated IGF1R signaling. Mol Cancer Res (2012) 0.86
Epigenetic silencing of EYA2 in pancreatic adenocarcinomas promotes tumor growth. Oncotarget (2014) 0.85
Pathology and molecular genetics of pancreatic neoplasms. Cancer J (2012) 0.85
Transcriptome analysis of pancreatic cancer reveals a tumor suppressor function for HNF1A. Carcinogenesis (2014) 0.85
Sox9: a master regulator of the pancreatic program. Rev Diabet Stud (2014) 0.84
Modulation of EZH2 Expression by MEK-ERK or PI3K-AKT Signaling in Lung Cancer Is Dictated by Different KRAS Oncogene Mutations. Cancer Res (2015) 0.84
Activated wnt signaling in stroma contributes to development of pancreatic mucinous cystic neoplasms. Gastroenterology (2013) 0.83
Pathological and molecular evaluation of pancreatic neoplasms. Semin Oncol (2014) 0.83
Preclinical models of pancreatic ductal adenocarcinoma. J Pathol (2015) 0.83
Nonviral oncogenic antigens and the inflammatory signals driving early cancer development as targets for cancer immunoprevention. Clin Cancer Res (2015) 0.83
[New insights into the origin of pancreatic cancer. Role of atypical flat lesions in pancreatic carcinogenesis]. Pathologe (2012) 0.83
Cancer of the Pancreas: Molecular Pathways and Current Advancement in Treatment. J Cancer (2016) 0.83
Cancer immunoprevention--the next frontier. Cancer Prev Res (Phila) (2014) 0.82
The roles of FOXM1 in pancreatic stem cells and carcinogenesis. Mol Cancer (2013) 0.82
Activating GNAS and KRAS mutations in gastric foveolar metaplasia, gastric heterotopia, and adenocarcinoma of the duodenum. Br J Cancer (2015) 0.82
Pancreatic adenocarcinoma pathology: changing "landscape". J Gastrointest Oncol (2015) 0.82
An angiopoietin-like protein 2 autocrine signaling promotes EMT during pancreatic ductal carcinogenesis. Oncotarget (2015) 0.81
Cytopathological Analysis of Cyst Fluid Enhances Diagnostic Accuracy of Mucinous Pancreatic Cystic Neoplasms. Medicine (Baltimore) (2015) 0.81
The transcription factor GLI1 modulates the inflammatory response during pancreatic tissue remodeling. J Biol Chem (2014) 0.81
In vivo serial selection of human pancreatic cancer cells in orthotopic mouse models produces high metastatic variants irrespective of Kras status. J Surg Res (2013) 0.81
YAP1 and TAZ Control Pancreatic Cancer Initiation in Mice by Direct Up-regulation of JAK-STAT3 Signaling. Gastroenterology (2016) 0.81
Selective impact of CDK4/6 suppression on patient-derived models of pancreatic cancer. Oncotarget (2015) 0.80
Differential in vivo tumorigenicity of diverse KRAS mutations in vertebrate pancreas: A comprehensive survey. Oncogene (2014) 0.80
GNAS is not involved in gastrointestinal tumour formation in Peutz-Jeghers syndrome. Fam Cancer (2013) 0.80
Adenocarcinoma of the pancreas. Semin Diagn Pathol (2014) 0.80
Anti-pancreatic cancer deliverables from sea: first-hand evidence on the efficacy, molecular targets and mode of action for multifarious polyphenols from five different brown-algae. PLoS One (2013) 0.80
Noncoding RNAs and pancreatic cancer. World J Gastroenterol (2016) 0.79
GNAS mutation is a frequent event in pancreatic intraductal papillary mucinous neoplasms and associated adenocarcinomas. Virchows Arch (2015) 0.79
The Triple-Code Model for Pancreatic Cancer: Cross Talk Among Genetics, Epigenetics, and Nuclear Structure. Surg Clin North Am (2015) 0.79
Mitochondrial uncoupling protein 2 and pancreatic cancer: a new potential target therapy. World J Gastroenterol (2015) 0.78
Genomic landscapes of pancreatic neoplasia. J Pathol Transl Med (2015) 0.78
KRAS mutations in blood circulating cell-free DNA: a pancreatic cancer case-control. Oncotarget (2016) 0.78
Activation of WNT/β-Catenin Signaling Enhances Pancreatic Cancer Development and the Malignant Potential Via Up-regulation of Cyr61. Neoplasia (2016) 0.77
Genome-scale analysis identifies GJB2 and ERO1LB as prognosis markers in patients with pancreatic cancer. Oncotarget (2017) 0.77
Viro-immune therapy: A new strategy for treatment of pancreatic cancer. World J Gastroenterol (2016) 0.77
Insights Into SMAD4 Loss in Pancreatic Cancer From Inducible Restoration of TGF-β Signaling. Mol Endocrinol (2015) 0.77
Copy number gain of chromosome 3q is a recurrent event in patients with intraductal papillary mucinous neoplasm (IPMN) associated with disease progression. Oncotarget (2016) 0.77
KRAS Mutant Pancreatic Cancer: No Lone Path to an Effective Treatment. Cancers (Basel) (2016) 0.77
Circulating antibodies to p16 protein-derived peptides in breast cancer. Mol Clin Oncol (2015) 0.77
High-content, full genome siRNA screen for regulators of oncogenic HRAS-driven macropinocytosis. Assay Drug Dev Technol (2015) 0.77
A recombinantly tailored β-defensin that displays intensive macropinocytosis-mediated uptake exerting potent efficacy against K-Ras mutant pancreatic cancer. Oncotarget (2016) 0.77
Loss of p27Kip1 promotes metaplasia in the pancreas via the regulation of Sox9 expression. Oncotarget (2015) 0.77
Cells of origin of pancreatic neoplasms. Surg Today (2017) 0.77
Overexpression of ankyrin1 promotes pancreatic cancer cell growth. Oncotarget (2016) 0.76
GLP-1 receptor agonist effects on normal and neoplastic pancreata. Diabetes (2012) 0.76
Identification of KCa3.1 Channel as a Novel Regulator of Oxidative Phosphorylation in a Subset of Pancreatic Carcinoma Cell Lines. PLoS One (2016) 0.76
Detection of Tumor Suppressor Genes in Cancer Development by a Novel shRNA-Based Method. Mol Cancer Res (2015) 0.76
Extracellular vesicles for liquid biopsy in prostate cancer: where are we and where are we headed? Prostate Cancer Prostatic Dis (2017) 0.76
ER stress protein AGR2 precedes and is involved in the regulation of pancreatic cancer initiation. Oncogene (2016) 0.75
Human pancreatic cancer progression: an anarchy among CCN-siblings. J Cell Commun Signal (2016) 0.75
Identification of KIAA1199 as a Biomarker for Pancreatic Intraepithelial Neoplasia. Sci Rep (2016) 0.75
Epithelial to Stromal Re-Distribution of Primary Cilia during Pancreatic Carcinogenesis. PLoS One (2016) 0.75
Proteasome activity is required for the initiation of precancerous pancreatic lesions. Sci Rep (2016) 0.75
Immune checkpoint and inflammation as therapeutic targets in pancreatic carcinoma. World J Gastroenterol (2016) 0.75
Stromal ETS2 Regulates Chemokine Production and Immune Cell Recruitment during Acinar-to-Ductal Metaplasia. Neoplasia (2016) 0.75
Pancreatic cancer from bench to bedside: molecular pathways and treatment options. Ann Transl Med (2016) 0.75
Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science (2008) 36.02
Preinvasive and invasive ductal pancreatic cancer and its early detection in the mouse. Cancer Cell (2003) 15.43
Pancreatic cancer. Lancet (2011) 8.54
Recurrent GNAS mutations define an unexpected pathway for pancreatic cyst development. Sci Transl Med (2011) 5.03
Senescence-messaging secretome: SMS-ing cellular stress. Nat Rev Cancer (2009) 5.02
Progression model for pancreatic cancer. Clin Cancer Res (2000) 4.60
Gene expression profiles in pancreatic intraepithelial neoplasia reflect the effects of Hedgehog signaling on pancreatic ductal epithelial cells. Cancer Res (2005) 2.64
Telomere shortening is nearly universal in pancreatic intraepithelial neoplasia. Am J Pathol (2002) 2.44
When cells get stressed: an integrative view of cellular senescence. J Clin Invest (2004) 2.37
Frequency of K-ras mutations in pancreatic intraductal neoplasias associated with pancreatic ductal adenocarcinoma and chronic pancreatitis: a meta-analysis. Neoplasia (2005) 2.03
Pancreatic duct glands are distinct ductal compartments that react to chronic injury and mediate Shh-induced metaplasia. Gastroenterology (2009) 1.78
Increased Prevalence of Precursor Lesions in Familial Pancreatic Cancer Patients. Clin Cancer Res (2009) 1.65
Oncogenic KRas suppresses inflammation-associated senescence of pancreatic ductal cells. Cancer Cell (2010) 1.58
Genome-wide analysis of promoter methylation associated with gene expression profile in pancreatic adenocarcinoma. Clin Cancer Res (2011) 1.52
A second generation human haplotype map of over 3.1 million SNPs. Nature (2007) 85.39
The consensus coding sequences of human breast and colorectal cancers. Science (2006) 60.02
An integrated genomic analysis of human glioblastoma multiforme. Science (2008) 51.36
The genomic landscapes of human breast and colorectal cancers. Science (2007) 38.12
Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science (2008) 36.02
IDH1 and IDH2 mutations in gliomas. N Engl J Med (2009) 32.41
High frequency of mutations of the PIK3CA gene in human cancers. Science (2004) 27.94
International network of cancer genome projects. Nature (2010) 20.35
Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer. Science (2009) 18.40
Distant metastasis occurs late during the genetic evolution of pancreatic cancer. Nature (2010) 17.38
Genome-wide detection and characterization of positive selection in human populations. Nature (2007) 17.27
Preinvasive and invasive ductal pancreatic cancer and its early detection in the mouse. Cancer Cell (2003) 15.43
Transactivation of miR-34a by p53 broadly influences gene expression and promotes apoptosis. Mol Cell (2007) 14.58
Trp53R172H and KrasG12D cooperate to promote chromosomal instability and widely metastatic pancreatic ductal adenocarcinoma in mice. Cancer Cell (2005) 14.21
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med (2015) 13.08
Elucidation of a universal size-control mechanism in Drosophila and mammals. Cell (2007) 13.04
Transforming single DNA molecules into fluorescent magnetic particles for detection and enumeration of genetic variations. Proc Natl Acad Sci U S A (2003) 12.91
Prepublication data sharing. Nature (2009) 12.24
The colorectal microRNAome. Proc Natl Acad Sci U S A (2006) 11.59
Allelic variation in human gene expression. Science (2002) 11.42
Exome sequencing of head and neck squamous cell carcinoma reveals inactivating mutations in NOTCH1. Science (2011) 11.12
Frequent mutations of chromatin remodeling gene ARID1A in ovarian clear cell carcinoma. Science (2010) 10.78
Comparative lesion sequencing provides insights into tumor evolution. Proc Natl Acad Sci U S A (2008) 10.52
Circulating mutant DNA to assess tumor dynamics. Nat Med (2007) 10.33
DAXX/ATRX, MEN1, and mTOR pathway genes are frequently altered in pancreatic neuroendocrine tumors. Science (2011) 10.26
The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers. Nature (2012) 10.17
Oncogene-induced Nrf2 transcription promotes ROS detoxification and tumorigenesis. Nature (2011) 9.70
DNMT1 and DNMT3b cooperate to silence genes in human cancer cells. Nature (2002) 9.40
EMT and dissemination precede pancreatic tumor formation. Cell (2012) 9.27
Using the transcriptome to annotate the genome. Nat Biotechnol (2002) 9.04
Epidermal electronics. Science (2011) 8.65
Pancreatic cancer. Lancet (2011) 8.54
Detection of circulating tumor DNA in early- and late-stage human malignancies. Sci Transl Med (2014) 8.36
The genetic landscape of the childhood cancer medulloblastoma. Science (2010) 8.34
Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes. Nature (2012) 8.31
The genome of the mesopolyploid crop species Brassica rapa. Nat Genet (2011) 8.23
The genome of the cucumber, Cucumis sativus L. Nat Genet (2009) 8.19
Widespread requirement for Hedgehog ligand stimulation in growth of digestive tract tumours. Nature (2003) 8.14
Mutant PIK3CA promotes cell growth and invasion of human cancer cells. Cancer Cell (2005) 7.87
Tumorigenesis: RAF/RAS oncogenes and mismatch-repair status. Nature (2002) 7.46
Exomic sequencing identifies PALB2 as a pancreatic cancer susceptibility gene. Science (2009) 7.39
1423 pancreaticoduodenectomies for pancreatic cancer: A single-institution experience. J Gastrointest Surg (2006) 7.18
Pancreatic cancer. Annu Rev Pathol (2008) 6.96
TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal. Proc Natl Acad Sci U S A (2013) 6.88
Hedgehog signalling in prostate regeneration, neoplasia and metastasis. Nature (2004) 6.82
A draft sequence for the genome of the domesticated silkworm (Bombyx mori). Science (2004) 6.62
DPC4 gene status of the primary carcinoma correlates with patterns of failure in patients with pancreatic cancer. J Clin Oncol (2009) 6.43
The antisense transcriptomes of human cells. Science (2008) 6.29
Detection and quantification of rare mutations with massively parallel sequencing. Proc Natl Acad Sci U S A (2011) 6.29
Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a randomized, double-blind, placebo-controlled phase III study. J Clin Oncol (2011) 6.18
Gemcitabine plus nab-paclitaxel is an active regimen in patients with advanced pancreatic cancer: a phase I/II trial. J Clin Oncol (2011) 6.16
Development of personalized tumor biomarkers using massively parallel sequencing. Sci Transl Med (2010) 6.08
The structure of a human p110alpha/p85alpha complex elucidates the effects of oncogenic PI3Kalpha mutations. Science (2007) 6.01
Detection and quantification of mutations in the plasma of patients with colorectal tumors. Proc Natl Acad Sci U S A (2005) 5.91
Inactivation of hCDC4 can cause chromosomal instability. Nature (2004) 5.71
An in vivo platform for translational drug development in pancreatic cancer. Clin Cancer Res (2006) 5.52
Mutational analysis of the tyrosine kinome in colorectal cancers. Science (2003) 5.43
Colorectal cancer: mutations in a signalling pathway. Nature (2005) 5.42
Notch mediates TGF alpha-induced changes in epithelial differentiation during pancreatic tumorigenesis. Cancer Cell (2003) 5.36
Glucose deprivation contributes to the development of KRAS pathway mutations in tumor cells. Science (2009) 5.31
Epitope landscape in breast and colorectal cancer. Cancer Res (2008) 5.29
A genetic variation map for chicken with 2.8 million single-nucleotide polymorphisms. Nature (2004) 5.24
A protocol for rapid generation of recombinant adenoviruses using the AdEasy system. Nat Protoc (2007) 5.15
Genome-wide association study identifies variants in the ABO locus associated with susceptibility to pancreatic cancer. Nat Genet (2009) 5.14
Intraductal papillary mucinous neoplasms of the pancreas: an updated experience. Ann Surg (2004) 5.12
Blockade of hedgehog signaling inhibits pancreatic cancer invasion and metastases: a new paradigm for combination therapy in solid cancers. Cancer Res (2007) 5.12
Recurrent GNAS mutations define an unexpected pathway for pancreatic cyst development. Sci Transl Med (2011) 5.03
Inhibition of lactate dehydrogenase A induces oxidative stress and inhibits tumor progression. Proc Natl Acad Sci U S A (2010) 4.97
Genome sequence of Shigella flexneri 2a: insights into pathogenicity through comparison with genomes of Escherichia coli K12 and O157. Nucleic Acids Res (2002) 4.92
Cancer-specific high-throughput annotation of somatic mutations: computational prediction of driver missense mutations. Cancer Res (2009) 4.92
A genome-wide association study identifies pancreatic cancer susceptibility loci on chromosomes 13q22.1, 1q32.1 and 5p15.33. Nat Genet (2010) 4.89